by Ashwin Kulkarni | Dec 16, 2020 | Uncategorized
Anthony Saleh’s biotech, miRecule, is using microRNA therapeutics to treat cancers. This seed round will send the startup into the next phase of its journey toward clinical trials. – Washington Business Journal
by Ashwin Kulkarni | Dec 16, 2020 | Uncategorized
Integrated genomic and functional microRNA analysis identifies miR-30-5p as a tumor suppressor and potential therapeutic nanomedicine in head and neck cancer – Clinical Cancer Research
by Ashwin Kulkarni | Dec 16, 2020 | Uncategorized
miRecule closes Seed Round at the second annual BioHealth Capital Region Investment Conference – BioBuzz
by Ashwin Kulkarni | Dec 16, 2020 | Uncategorized
miRecule, Inc., is developing a novel treatment for FSHD – FSHD Society
by Ashwin Kulkarni | Dec 16, 2020 | Uncategorized
Antisense Oligonucleotide-Antibody Conjugates to Treat FSHD – Friends of FSH Research
by Ashwin Kulkarni | Dec 16, 2020 | Uncategorized
USM Maryland Momentum Fund Invests $250,000 in $3.5M Seed Round of miRecule Inc. – USM Momentum Fund
